Payment overview · 2025
General Payments
$416.53
20 reported records · 11 companies
Healthcare provider profile · identity verified
Munira A Khambati, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MARBLE FALLS, TX · NPI 1215958624
Verified facts
What the public records show
CMS Open Payments records show Munira A Khambati, M.D. received $416.53 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.43 | 19.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.44 | 15.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.17 | 14.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.12 | 10.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.32 | 9.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.13 | 7.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.78 | 6.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.66 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.02 | 4.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.93 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.53 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.53 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.43 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.12 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 781 | 222 |
| Atorvastatin Calcium | Atorvastatin Calcium | 671 | 197 |
| Lisinopril | Lisinopril | 448 | 137 |
| Gabapentin | Gabapentin | 447 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 396 | 119 |
| Losartan Potassium | Losartan Potassium | 367 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 83 |
| Omeprazole | Omeprazole | 283 | 84 |
| Trazodone Hcl | Trazodone Hcl | 237 | 61 |
| Metformin Hcl | Metformin Hcl | 229 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 197 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 76 |
| Simvastatin | Simvastatin | 191 | 57 |
| Sertraline Hcl | Sertraline Hcl | 172 | 46 |
| Metformin Hcl Er | Metformin Hcl | 167 | 47 |
| Meloxicam | Meloxicam | 158 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 155 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 37 |
| Montelukast Sodium | Montelukast Sodium | 151 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 44 |
| Pioglitazone Hcl | Pioglitazone Hcl | 145 | 34 |
| Lovastatin | Lovastatin | 134 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 41 |
| Allopurinol | Allopurinol | 127 | 36 |
| Furosemide | Furosemide | 124 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 37 |
| Ozempic | Semaglutide | 120 | 23 |
| Potassium Chloride | Potassium Chloride | 114 | 32 |
| Glimepiride | Glimepiride | 110 | 26 |
| Azithromycin | Azithromycin | 109 | 95 |
| Temazepam | Temazepam | 106 | 28 |
| Tramadol Hcl | Tramadol Hcl | 105 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 24 |
| Bupropion Xl | Bupropion Hcl | 97 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 91 | 79 |
| Synthroid | Levothyroxine Sodium | 90 | 26 |
| Alendronate Sodium | Alendronate Sodium | 88 | 31 |
| Alprazolam | Alprazolam | 86 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | 27 |
| Lorazepam | Lorazepam | 78 | 21 |
| Glipizide | Glipizide | 73 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 18 |
| Carvedilol | Carvedilol | 72 | 18 |
| Famotidine | Famotidine | 72 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 37 |
| Atenolol | Atenolol | 63 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 19 |
| Celecoxib | Celecoxib | 62 | 16 |
| Jardiance | Empagliflozin | 61 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 55 |
| Methocarbamol | Methocarbamol | 59 | 26 |
| Mirtazapine | Mirtazapine | 58 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 16 |
| Buspirone Hcl | Buspirone Hcl | 53 | 12 |
| Ezetimibe | Ezetimibe | 53 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 14 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 16 |
| Estradiol | Estradiol | 48 | 20 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Myrbetriq | Mirabegron | 44 | 12 |
| Glipizide Er | Glipizide | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 42 | 17 |
| Cefuroxime | Cefuroxime Axetil | 41 | 36 |
| Finasteride | Finasteride | 38 | 11 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | 11 |
| Cephalexin | Cephalexin | 36 | 30 |
| Eliquis | Apixaban | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 15 |
| Acyclovir | Acyclovir | 30 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Etodolac | Etodolac | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 12 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | 14 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.53 · 20 records | Novo Nordisk Inc | BREZTRI, DAYBUE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, The Cologuard Plus Collection Kit, Tymlos, VOQUEZNA, Veozah, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error